RUBRACA (rucaparib) tablets
Rubraca is a prescription medicine used in adults for: • the maintenance treatment of ovarian cancer, fallopian tube cancer, or primary peritoneal cancer • the treatment of castration-resistant prostate cancer. Brand: RUBRACA (rucaparib) tablets, for oral use Initial U.S. Approval: 2016
Home | (rucaparib) tablets
Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!
For Indian Patient inquires under NPP.
Call / WhatsApp Number
+91 9289711088 (Ms. Laxmi Singh)
For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.
RUBRACA (rucaparib) tablets
Rucaparib camsylate is approved to treat: Ovarian epithelial, fallopian tube, or primary peritoneal cancer, Prostate cancer. Rucaparib camsylate is also being studied in the treatment of other types of cancer.
Rubraca, A drug used to treat adults with certain types of prostate cancer or ovarian epithelial, fallopian tube, or primary peritoneal cancer. It is also being studied in the treatment of other types of cancer. Rubraca blocks an enzyme involved in many cell functions, including the repair of DNA damage. Blocking this enzyme may help keep cancer cells from repairing their damaged DNA, causing them to die. Rubraca is a type of PARP inhibitor. Also called AG014699, PARP-1 inhibitor AG014699, and rucaparib camsylate.
Rucaparib Camsylate , A drug used to treat adults with certain types of prostate cancer or ovarian epithelial, fallopian tube, or primary peritoneal cancer. It is also being studied in the treatment of other types of cancer. Rucaparib camsylate blocks an enzyme involved in many cell functions, including the repair of DNA damage. Blocking this enzyme may help keep cancer cells from repairing their damaged DNA, causing them to die. Rucaparib camsylate is a type of PARP inhibitor. Also called AG014699, PARP-1 inhibitor AG014699, and Rubraca.
Drug (Brand / Generic): RUBRACA / rucaparib
Current Indications: prostate cancer or ovarian epithelial, fallopian tube, or primary peritoneal cancer
Marketed by:: Clovis Oncology, Inc
Approval Date: October 27, 2009
Available as (Form & Strength): Tablets: 200 mg, 250 mg, and 300 mg
For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here
Alleviare Life Sciences
About Us
Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.
Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.
Alleviare India is certified pharmaceutical facilitator / supplier /importer based in india. They are also who GDP certified. One of the pharmaceutical products they offer is “RUBRACA (rucaparib) tablets”.
Confirmation of the order for RUBRACA (rucaparib) tablets will be subject to the submission of a valid doctor’s prescription and, if applicable, an import permit.
We have delivered medicines to following cities in India – Ahmedabad, Aizawal, Aurangabad, Barshi, Bengaluru, Bhopal, Cachar, Chennai, Dibrugarh, Hyderabad, Karungapally, Kohima, Kollam, Kolkata, Mumbai, Meghalaya, Mizoram, Sikkim, Nagpur, New Delhi, Pondichery, Pune, Punjab, Thirunananthapuram, Tripura, Wardha
ALS serves as a facilitator, supplier & exporter in India assisting patients, doctors, and hospitals in importing the prescription medicine brand RUBRACA (rucaparib) tablets. The import process requires a valid prescription and an Import License in the Patient’s Name.
For patients from following foreign countries seeking access to RUBRACA (rucaparib) tablets. they can inquire and find further information by sending their inquiries to ALS.
We have delivered medicines to following countries – Argentina, Australia, Austria, Azerbaijan, Bahrain, Brazil, Bulgaria, Cambodia, Canada, Chile, Colombia, Costa Rica, Croatia, Cyprus, Denmark, Dominican Republic, Estonia, Finland, France, Georgia, Germany, Ghana, Greece, Guatemala, India, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kenya, Kuwait, Latvia, Lebanon, Libya, Lithuania, Malawi, Mexico, Montenegro, Nepal, Netherlands, New Zealand, Nigeria, Norway, Oman, Pakistan, Paraguay, Peru, Poland, Qatar, Romania, Saudi Arabia, Serbia, Singapore, Slovenia, Spain, Sri Lanka, Sweden, Switzerland, United Arab Emirates, United Kingdom, United States, Venezuela, Zimbabwe.
Kindly reach out to us for RUBRACA (rucaparib) tablets price and availability confirmation.
The price of the medicines is the cost set by the manufacturer. In addition, Named Patient support fee, shipping costs and any local tax (if applicable) will apply.
